Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 16 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 9566329

    Live, attenuated rubella vector to express vaccine antigens

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted

  2. US 9556438

    Gene vector

    FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted

  3. US 9550818

    Methods for use of vascular endothelial growth factor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted

  4. US 9546176

    Small molecule bicyclic and tricyclic CFTR correctors

    DISCOVERYBIOMED, INC. · Granted Jan 17, 2017 · Expires Jan 12, 2037

    granted

  5. US 9545442

    Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 17, 2017 · Expires Jan 12, 2037

    granted

  6. US 9540440

    Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 10, 2017 · Expires Jan 5, 2037

    granted

  7. US 9526777

    Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein

    The United States of America, as represented by the Department of Health and Human Services · Granted Dec 27, 2016 · Expires Dec 22, 2036

    granted

  8. US 9522955

    Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 20, 2016 · Expires Dec 15, 2036

    granted

  9. US 9506926

    Molecular predictors of therapeutic response to specific anti-cancer agents

    The Regents of the University of California · Granted Nov 29, 2016 · Expires Nov 24, 2036

    granted

  10. US 9504762

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Nov 29, 2016 · Expires Nov 24, 2036

    granted

  11. US 9492430

    Methods and compositions associated with the granulocyte colony-stimulating factor receptor

    Ligand Pharmaceuticals Incorporated · Granted Nov 15, 2016 · Expires Nov 10, 2036

    granted

  12. US 9493757

    Modified factor VII or factor VIIa polypeptides

    Regents of the University of Minnesota · Granted Nov 15, 2016 · Expires Nov 10, 2036

    granted

  13. US 9493544

    Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

    Nektar Therapeutics · Granted Nov 15, 2016 · Expires Nov 10, 2036

    granted

  14. US 9492415

    Methods of treating Parkinson's disease using viral vectors

    The Regents of the University of California · Granted Nov 15, 2016 · Expires Nov 10, 2036

    granted

  15. US 9476037

    Factor VII polypeptides that are modified and uses thereof

    Catalyst Biosciences, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted

  16. US 9468649

    Methods of treating epilepsy with transforming growth factor beta inhibitors

    The Regents of the University of California · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted

  17. US 9447419

    RNAi-mediated inhibition of tumor necrosis factor α-related conditions

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted

  18. US 9439979

    Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 13, 2016 · Expires Sep 8, 2036

    granted

  19. US 9441225

    Compositions and methods for inhibiting expression of factor V

    Alnylam Pharmaceuticals, Inc. · Granted Sep 13, 2016 · Expires Sep 8, 2036

    granted

  20. US 9353178

    Stem cell factor inhibitor

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 31, 2016 · Expires May 26, 2036

    granted

  21. US 9352027

    Albumin-free factor VIII formulations

    UNIVERSITY OF CONNECTICUT · Granted May 31, 2016 · Expires May 26, 2036

    granted

  22. US 9347054

    Polymer factor IX moiety conjugates

    Nektar Therapeutics · Granted May 24, 2016 · Expires May 19, 2036

    granted

  23. US 9328339

    Modified factor IX polypeptides and uses thereof

    Catalyst Biosciences, Inc. · Granted May 3, 2016 · Expires Apr 28, 2036

    granted

  24. US 9309535

    Combination anti-HIV vectors, targeting vectors, and methods of use

    The Regents of the University of California · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.